Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Johnson & Johnson — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.73 (market cap $157.51B), while Johnson & Johnson trades at $258 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 4× Banco Bilbao Vizcaya Argentaria SA's market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| BBVA | JNJ | |
|---|---|---|
Market Cap | $157.51B | $626.09B |
Sector | Financials | Health |
52-Week High | $28.50 | $267.24 |
52-Week Low | $17.96 | $172.78 |
Dividend Yield | 3.8% | 2.06% |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $28.35 with a bullish technical outlook, supported by moving averages and a strong ADX trend indicator. The company reported robust Q2 2026 earnings, beating EPS estimates with $0.63 actual versus $0.59 expected, driven by loan growth and a new $2.3 billion share buyback announcement. Revenue reached $39.42 billion in 2025, with net income of $10.51 billion and a rising profit margin of 26.66%.
Outlook remains positive with analyst consensus leaning buy (53.85%) and a projected revenue increase to $42.5 billion in 2026. Key risks include regulatory probes in Spain and volatile cash flow trends, but strong profitability and institutional support suggest upside potential for investors seeking European bank exposure.
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
